ALC
Alcon Inc.
ALC has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over ALC overall, supported by stronger fundamentals and stronger modeled upside.
ALC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
ALC's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ALC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $71.83 | — |
| Cheap | 39x | $50.05 | -30% |
| Fair | 48x | $62.50 | -13% |
| Current | 55x | $71.83 | — |
| Expensive | 108x | $140 | +95% |
Historical ranges are pointers, not guarantees.
ALC's PE is in its fair range at 55x. If earnings grow as analysts expect, today's price would be 19x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ALC in the historical PE scenario, which offers more potential upside but is not a forecast.
ALC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for ALC, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ALC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.85 | +196% |
| Q2 2026 | $1.30 | -40% |
| Q1 2026 | $1.65 | -27% |
| Q4 2025 | $1.97 | -3.9% |
| Q3 2025 | $2.10 | -11% |
| Q2 2025 | $2.15 | -3.6% |
| Q1 2025 | $2.25 | +6.1% |
| Q4 2024 | $2.05 | +4.1% |
| Q3 2024 | $2.35 | +161% |
ALC's earnings per share have fallen from their peak: $1.30 over the past year, against $2.35 in late 2024.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over ALC on earnings, with more consistent year-over-year improvement.
ALC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2.8B | +8.7% |
| Q1 2026 | $2.7B | +7.3% |
| Q4 2025 | $2.7B | +8.6% |
| Q3 2025 | $2.6B | +6.5% |
| Q2 2025 | $2.6B | +4% |
| Q1 2025 | $2.5B | +0.6% |
| Q4 2024 | $2.5B | +6.4% |
| Q3 2024 | $2.5B | +5.4% |
ALC's revenue has grown year over year for 23 quarters in a row: $2.8B last quarter, up 8.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 0.4% | -9.1 points |
| Q1 2026 | 15% | -3.4 points |
| Q4 2025 | 12% | -4.3 points |
| Q3 2025 | 13% | -0.8 points |
| Q2 2025 | 9.5% | -3.2 points |
| Q1 2025 | 19% | +4 points |
| Q4 2024 | 16% | +6.9 points |
| Q3 2024 | 14% | +0.9 points |
ALC's operating margin was 0.4% last quarter, down 9.1 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ALC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ALC on profitability, with a higher operating margin.
ALC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $414M | +11% |
| Q1 2026 | $273.6M | +12% |
| Q4 2025 | $457M | +46% |
| Q3 2025 | $538.7M | -12% |
| Q2 2025 | $372M | -9.3% |
| Q1 2025 | $244M | +23% |
| Q4 2024 | $313.2M | +186% |
| Q3 2024 | $613.2M | +69% |
ALC generated $1.7B in free cash flow over the past year, up 9.1% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
ALC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.5M shares |
| 1 year | -1.8% | -9.2M shares |
| 3 years | -1.4% | -7M shares |
| 5 years | -0.9% | -4.5M shares |
| Available history | +0.1% | +500K shares |
ALC has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $289M |
| Q1 2026 | $73.5M |
| Q4 2025 | $308M |
| Q3 2025 | $250.5M |
| Q2 2025 | $126M |
| Q1 2025 | $33M |
| Q4 2024 | $2M |
| Q3 2024 | $3M |
ALC spent $921M buying back its own shares over the past year, about six times what it spent the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ALC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.4x | Healthy |
| Q1 2026 | 1.4x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.4x | Healthy |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.3x | Healthy |
| Q3 2024 | 1.4x | Healthy |
ALC's net debt is about 1.4 years of its operating earnings (EBITDA), about the same as a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ALC on leverage, with a lower net debt burden relative to earnings.
ALC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.0 | Neutral |
| Stochastic | 69.9 | Neutral |
ALC's weekly RSI is 53 (neutral) and its Stochastic is 70 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ALC PE vs Healthcare Sector
| Metric | ALC | Sector median | Relative |
|---|---|---|---|
| PE | 55x | 26x | 114% above |
| PE % | 51 | 29 | 22 pts above |
ALC is trading at 55x earnings, a 114% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ALC on valuation relative to its sector.
ALC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $68.4 | 5.1% above |
| 20 week MA | $69.2 | 3.7% above |
| 50 week MA | $72.9 | 1.5% below |
| 100 week MA | $79.1 | 9.2% below |
| 200 week MA | $80.6 | 11% below |
ALC has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 11% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ALC on trend strength, trading above more of its moving averages.
ALC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $57.4 | $64.9 | +13% |
| 2021 | $64.9 | $86.6 | +34% |
| 2022 | $86.6 | $67.8 | -22% |
| 2023 | $67.8 | $78.1 | +15% |
| 2024 | $78.1 | $85.7 | +9.6% |
| 2025 | $85.7 | $80.4 | -6.2% |
| 2026 YTD | $80.4 | $71.8 | -11% |
ALC has finished higher in four of the last six years. It's down 11% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ALC on returns for 2026, with the stronger performance.